Today it was announced that Thomas Tan has joined the Sound Bioventures team as a Principal. Thomas will identify new investment opportunities, conduct scientific and commercial due diligence, and participate in board work.
Prior to joining Sound Bioventures, Thomas was a senior principal at Lundbeckfonden Ventures, were he identified and managed investments, and was a board member at Atox Bio and VarmX. Prior to his position at Lundbeckfonden Ventures, he worked as a strategy consultant at LSD, Huron and Deallus advising biotech and pharma on portfolio strategy, product positioning and pricing. Before that Thomas started his own biotech company in Cambridge, UK.
Thomas received his postdoctoral training at University of Cambridge, UK after earning his D. Phil. in Medical Sciences from University of Oxford, UK, and his M.Sc. in Biochemistry from University of Copenhagen, DK.
Thomas will be based in the Copenhagen, Denmark, office.
Thomas Tan joins Sound Bioventures
The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health
Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Breye Therapeutics ApS announced their collaboration to develop the P2X7 receptor antagonist programme. Breye Therapeutics, a clinical-stage pharmaceutical co ...
From Doctor To Investor: How My MBA Kickstarted An Exciting Career In Life Sciences Venture Capital
Aiming to make an impact in his career, certified medical doctor Philip Brainin combined his healthcare expertise with an MBA to launch a career in life sciences venture capital A keen interest in learning and a desire to help others have defined Philip Brainin’s career so far. Today he is an analyst with a specialist […]
Sound Bioventures appoints Fredrik Lehmann as its first Entrepreneur-in-Residence
Stockholm, Sweden and Cambridge, MA, USA – 13 October 2023 – Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced that Fredrik Lehmann, Ph.D., MBA has joined the company as its first Entrepreneur-in-Residence. Fr ...
At the intersection of entrepreneurship, life science, & patient needs
Fredrik Lehmann, Entrepreneur in Residence at Sound Bioventures, explains how success in life science takes tenacity and constant focus on patient needs.